Australia · Delayed Price · Currency is AUD 4DMedical Statistics
Total Valuation
4DMedical has a market cap or net worth of AUD 2.38 billion. The enterprise value is 2.28 billion.
| Market Cap | 2.38B |
| Enterprise Value | 2.28B |
Important Dates
The next estimated earnings date is Thursday, November 26, 2026.
| Earnings Date | Nov 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
4DMedical has 601.57 million shares outstanding. The number of shares has increased by 14.09% in one year.
| Current Share Class | 601.57M |
| Shares Outstanding | 601.57M |
| Shares Change (YoY) | +14.09% |
| Shares Change (QoQ) | +39.87% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 24.61% |
| Float | 498.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 339.91 |
| PB Ratio | 14.11 |
| P/TBV Ratio | 22.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 30.79, with a Debt / Equity ratio of 1.06.
| Current Ratio | 30.79 |
| Quick Ratio | 30.52 |
| Debt / Equity | 1.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.59 |
| Interest Coverage | -0.34 |
Financial Efficiency
Return on equity (ROE) is -174.43% and return on invested capital (ROIC) is -17.14%.
| Return on Equity (ROE) | -174.43% |
| Return on Assets (ROA) | -15.61% |
| Return on Invested Capital (ROIC) | -17.14% |
| Return on Capital Employed (ROCE) | -16.14% |
| Weighted Average Cost of Capital (WACC) | 18.50% |
| Revenue Per Employee | 39,014 |
| Profits Per Employee | -1.13M |
| Employee Count | 181 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.77 |
Taxes
| Income Tax | -1.13M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.11% in the last 52 weeks. The beta is 1.84, so 4DMedical's price volatility has been higher than the market average.
| Beta (5Y) | 1.84 |
| 52-Week Price Change | +76.11% |
| 50-Day Moving Average | 3.88 |
| 200-Day Moving Average | 4.12 |
| Relative Strength Index (RSI) | 50.90 |
| Average Volume (20 Days) | 3,937,107 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4DMedical had revenue of AUD 7.06 million and -204.44 million in losses. Loss per share was -0.38.
| Revenue | 7.06M |
| Gross Profit | 6.62M |
| Operating Income | -57.46M |
| Pretax Income | -205.57M |
| Net Income | -204.44M |
| EBITDA | -56.02M |
| EBIT | -57.46M |
| Loss Per Share | -0.38 |
Balance Sheet
The company has 277.95 million in cash and 180.24 million in debt, with a net cash position of 97.72 million or 0.16 per share.
| Cash & Cash Equivalents | 277.95M |
| Total Debt | 180.24M |
| Net Cash | 97.72M |
| Net Cash Per Share | 0.16 |
| Equity (Book Value) | 170.16M |
| Book Value Per Share | 0.28 |
| Working Capital | 280.54M |
Cash Flow
In the last 12 months, operating cash flow was -31.27 million and capital expenditures -949,826, giving a free cash flow of -32.22 million.
| Operating Cash Flow | -31.27M |
| Capital Expenditures | -949,826 |
| Depreciation & Amortization | 1.44M |
| Net Borrowing | 8.91M |
| Free Cash Flow | -32.22M |
| FCF Per Share | -0.05 |
Margins
| Gross Margin | 93.77% |
| Operating Margin | -813.68% |
| Pretax Margin | -2,911.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4DMedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -14.09% |
| Shareholder Yield | -14.09% |
| Earnings Yield | -8.52% |
| FCF Yield | -1.34% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for 4DMedical is 4.37, which is 10.63% higher than the current price. The consensus rating is "Hold".
| Price Target | 4.37 |
| Price Target Difference | 10.63% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 142.38% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4DMedical has an Altman Z-Score of 3.79 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.79 |
| Piotroski F-Score | 3 |